에 대한 최신 뉴스 Novo Nordisk (OTC:NONOF) 주식

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

NOVO NORDISK A/S B NEW by Novo-Nordisk A/S

Comments

Novo Nordisk

뉴스

에 대한 최신 뉴스 Novo Nordisk (OTC:NONOF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌